Proteome Sciences plc (LON:PRM) has today announced that Mr Richard Dennis has today been appointed to the Board of Directors. As communicated on 3 April 2017, when he joined the
Proteome Sciences plc (LON:PRM) has today announced its audited results for the year ended 31 December 2017. Highlights: · 23% revenue growth to £3.38m, underpinned by 79% increase in sales and
Electrophoretics Ltd, a wholly owned subsidiary of Proteome Sciences plc (LON:PRM), is pleased to announce that it has signed an amendment to the exclusive License and Distribution Agreement with Pierce Biotechnology
The Directors look forward to updating shareholders on the Company’s performance, and on the outlook for 2018, at the time they announce their 2017 full year results which are scheduled
Jeremy Haigh, Chief Executive of Proteome Sciences LON:PRM, commented: “While progress was slower than we would have wished during 2017, particularly on the services side of the business where early
Proteome Sciences plc has this morning announced the receipt of Good Clinical Laboratory Practice (GCLP) accreditation which will now enable it to compete effectively for clinical stage contracts commanding routinely
Proteome Sciences’ Jeremy Haigh discusses their interim results for the 6 months to 30 June 2017 in this exclusive interview with DirectorsTalk
Proteome Sciences Plc (LON:PRM) CEO Jeremy Haigh joins DirectorsTalk to discuss the release of its Interim results for the six months ended 30 June 2017. Jeremy explains what has driven
Proteome Sciences LON:PRM has given DirectorsTalk its unaudited interim results for the six months ended 30 June 2017. Financial highlights: — Total revenues increased 21% to GBP1.36m (2016: GBP1.12m) —
Proteome Sciences plc LON:PRM that Randox Laboratories Ltd presented the first results from a prospective trial using its Rapid Stroke Array at the EuroMedLab 2017 meeting in Athens earlier this
© 2025 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
